Shares in dual-listed cancer diagnostics company Pacific Edge have fallen 15% today on news the United States Food and Drug Administration wants to regulate laboratory-developed tests such as its Cxbladder.
Pacific Edge said today the FDA had released for public comment rule changes that would have
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
